The EMA validated the marketing authorization application for varegacestat in adults with desmoid tumors.

The FDA approved talazoparib plus enzalutamide in HRR-mutated prostate cancer, ivonescimab improved survival in biliary tract cancer, and more.

Fox Chase researchers identified ANO6 as a potential pancreatic cancer target; blocking it slowed tumor growth and reduced immune suppression in preclinical studies.

Breakthroughs with daraxonrasib in pancreatic cancer pave the way for continued investment in understanding the fundamental biology of cancers.

Risvutatug rezetecan delayed progression vs gemcitabine and docetaxel in patients with osteosarcoma after 2 or more prior systemic therapies.

Sonesitatug vedotin is a potential new SOC in select Claudin 18.2–positive gastroesophageal carcinoma.